Appeal No. 2006-3290 Page 2
Application No. 10/072,823
The references relied upon by Examiner are:
Fujita et al. (‘016) UK 1 476 016 Jun. 10, 1977
Fujita et al. (‘434) JP S52-102434 Aug. 27, 1977
Matsui JP Sho 52-145509 Dec. 3, 1977
Son et al. (Son) JP Sho 57-167938 Oct. 16, 1982
Ito et al. (Ito) JP H11-236334 Aug. 31, 1999
GROUND OF REJECTION
Claims 1-9, 11-16, 18-23, 29-29 and 32-35 stand rejected under 35 U.S.C.
§ 103 as being unpatentable over the combination of any one of Son, ‘016 or
‘434 with either Ito or Matsui.
We affirm.
CLAIM GROUPING
Appellant does not separately group or argue the claims. Accordingly, the
claims will stand or fall together. Therefore, we limit our discussion to
representative independent claim 1. Claims 2-9, 11-16, 18-23, 26-29 and 32-35
will stand or fall together with claim 1. 37 C.F.R. § 41.37(c)(1)(vii) (July 2005).
DISCUSSION
Claim Construction:
Claim 1 is drawn to a composition that comprises two components:
(1) oridonin, a pharmaceutically acceptable salt or ester of oridonin, a
selectively substituted analog of oridonin, or a combination thereof; and
(2) lupulone, a pharmaceutically acceptable salt or ester of lupulone, a
selectively substituted analog of lupulone, or a combination thereof.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: September 9, 2013